Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cost-effectiveness trial of first-line antiretroviral regimens in treatment-naive adults with HIV
2014-004820-24Phase 4Terminated
- Sponsor
- Fundació Clínic per a la Recerca Biomèdica
- Start
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of darunavir, ritonavir, lamivudine, abacavir, rilpivirine and 4 more in human immunodeficiency virus infection (HIV) (3 arms), sponsored by Fundació Clínic per a la Recerca Biomèdica. Primary endpoints: Patient with virological failure or clinical progression and Cost-effectiveness at 48 weeks. Started Mar 2015; status: terminated.
02
Drugs
darunavirritonavirlamivudineabacavirrilpivirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2014-004820-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004820-24.